Previous close | 32.83 |
Open | 31.21 |
Bid | 33.84 x 0 |
Ask | 33.87 x 0 |
Day's range | 32.58 - 34.64 |
52-week range | 21.60 - 34.64 |
Volume | |
Avg. volume | 17,102,862 |
Market cap | 54.374B |
Beta (5Y monthly) | 0.04 |
PE ratio (TTM) | 19.62 |
EPS (TTM) | 1.73 |
Earnings date | N/A |
Forward dividend & yield | 0.62 (1.81%) |
Ex-dividend date | 15 May 2023 |
1y target est | 40.22 |
Chinese drugmaker Sichuan Kelun Pharmaceutical Co said on Monday that Merck & Co Inc was abandoning the joint development of two candidate cancer drugs which have yet to start clinical trials. Representatives for Merck did not immediately respond to a Reuters request for comment. The move comes days after Merck said it would pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs in a deal that could be worth up to $22 billion for the Japanese firm.